Literature DB >> 9799168

Effect of gender, age, transmission category, and antiretroviral therapy on the progression of human immunodeficiency virus infection using multistate Markov models. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

A Alioum1, V Leroy, D Commenges, F Dabis, R Salamon.   

Abstract

This article illustrates the use of time-homogeneous Markov models with covariates to estimate the AIDS incubation period distribution from prevalent cohorts and to evaluate the effect of factors such as gender, age, human immunodeficiency virus (HIV) transmission category, and antiretroviral therapy on disease progression. We applied this methodology to the analysis of data from a cohort of 3,027 patients enrolled from a hospital-based surveillance system of HIV infection in the Bordeaux University Hospital and four secondary public hospitals in southwestern France. A total of 998 individuals (33%) progressed to AIDS during a median follow-up period of 34 months. Based on a progressive three-state Markov model, the estimated mean and median incubation periods were 9.1 years [95% confidence interval (CI) = 8.7-9.6] and 7.5 years (95% CI = 7.2-7.9), respectively. Our analyses showed a similar disease progression in men and women; we observed a more rapid progression for older subjects compared with younger ones and for homosexual men compared with heterosexuals, intravenous drug users, and transfusion recipients, who had similar disease progression rates after adjusting for age. The use of antiretroviral therapy appeared to slow disease progression. Moreover, the results indicated that a combination therapy of zidovudine with another antiretroviral drug may be more efficient than zidovudine monotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9799168

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  8 in total

1.  Multi-state models in epidemiology.

Authors:  D Commenges
Journal:  Lifetime Data Anal       Date:  1999-12       Impact factor: 1.588

Review 2.  HIV disease and advanced age: an increasing therapeutic challenge.

Authors:  Roberto Manfredi
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

3.  HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011.

Authors:  Bohdan Nosyk; Jeong Min; Viviane D Lima; Benita Yip; Robert S Hogg; Julio S G Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

4.  Rapid dissemination of SIV follows multisite entry after rectal inoculation.

Authors:  Patricia Ribeiro Dos Santos; Magali Rancez; Jean-Luc Prétet; Alice Michel-Salzat; Valérie Messent; Anna Bogdanova; Anne Couëdel-Courteille; Evelyne Souil; Rémi Cheynier; Cécile Butor
Journal:  PLoS One       Date:  2011-05-09       Impact factor: 3.240

5.  Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach.

Authors:  Mar Masiá; Sergio Padilla; Santiago Moreno; Xavier Barber; Jose A Iribarren; Jorge Del Romero; Juan L Gómez-Sirvent; María Rivero; Francesc Vidal; Antonio A Campins; Félix Gutiérrez
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

6.  HIV Disease Progression Among Antiretroviral Therapy Patients in Zimbabwe: A Multistate Markov Model.

Authors:  Zvifadzo Matsena Zingoni; Tobias F Chirwa; Jim Todd; Eustasius Musenge
Journal:  Front Public Health       Date:  2019-11-15

7.  Time-homogeneous Markov process for HIV/AIDS progression under a combination treatment therapy: cohort study, South Africa.

Authors:  Claris Shoko; Delson Chikobvu
Journal:  Theor Biol Med Model       Date:  2018-01-18       Impact factor: 2.432

8.  Prediction of extended high viremia among newly HIV-1-infected persons in sub-Saharan Africa.

Authors:  Kimberly A Powers; Matthew A Price; Etienne Karita; Anatoli Kamali; William Kilembe; Susan Allen; Eric Hunter; Linda-Gail Bekker; Shabir Lakhi; Mubiana Inambao; Omu Anzala; Mary H Latka; Patricia E Fast; Jill Gilmour; Eduard J Sanders
Journal:  PLoS One       Date:  2018-04-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.